Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors

PURPOSE: To determine the maximum tolerated dose (MTD), toxicities, and pharmacodynamics effects of sirolimus combined with oral metronomic topotecan and cyclophosphamide in a pediatric population. MATERIALS AND METHODS: Patients who were 1 to 30 years of age with relapsed/refractory solid tumors (i...

Descripción completa

Detalles Bibliográficos
Autores principales: Vo, Kieuhoa T., Karski, Erin E., Nasholm, Nicole M., Allen, Shelly, Hollinger, Fabienne, Clay Gustafson, W., Long-Boyle, Janel R., Shiboski, Stephen, Matthay, Katherine K., DuBois, Steven G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410349/
https://www.ncbi.nlm.nih.gov/pubmed/27793021
http://dx.doi.org/10.18632/oncotarget.12904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410349/
https://www.ncbi.nlm.nih.gov/pubmed/27793021
http://dx.doi.org/10.18632/oncotarget.12904

Ejemplares similares